Skip to main content
Howard Hughes Medical Institute Author Manuscripts logoLink to Howard Hughes Medical Institute Author Manuscripts
. Author manuscript; available in PMC: 2014 Dec 4.
Published in final edited form as: Nature. 2013 Jun 13;498(7453):E4–E7. doi: 10.1038/nature12125

Properties of Native Brain α-Synuclein

Jacqueline Burré 1, Sandro Vivona 1,2,3,4, Jiajie Diao 1,2,3,4, Manu Sharma 1, Axel T Brunger 1,2,3,4,6, Thomas C Südhof 1,4,5,6,*
PMCID: PMC4255827  NIHMSID: NIHMS644770  PMID: 23765500

α-Synuclein is an abundant presynaptic protein that binds to negatively charged phospholipids1,2, functions as a SNARE-complex chaperone3, and contributes to Parkinson’s Disease pathogenesis4,5. Recombinant α-synuclein in solution is largely unfolded and devoid of tertiary structure611, but Bartels et al. (2011) suggested that native α-synuclein purified from human erythrocytes forms a stably folded, soluble tetramer that resists aggregation12. In contrast, we here show that native α-synuclein purified from mouse brain consists of a largely unstructured monomer, exhibits no stable tetramer formation, and is prone to aggregation. The native state of α-synuclein is important for understanding its pathological effects since a stably folded protein would be much less prone to aggregation than a conformationally labile protein.

We examined native α-synuclein from brain, the most relevant organ for understanding neurodegeneration. Separation of mouse brain homogenates into soluble and membrane fractions revealed that during ultracentrifuation, most α-synuclein partitioned into cytosol fractions similar to complexins, but different from membrane proteins such as CSPα and SNAP-25 (Figs. 1a and 1b). Using gel filtration, we analyzed the size of native α-synuclein in brain cytosol and of recombinant myc-epitope tagged human α-synuclein, purified without boiling or detergents3. Both α-synucleins eluted in a single peak with an apparent molecular mass of ~63 kDa (Figs. 1c1f), close to that predicted for a folded tetramer12.

Figure 1.

Figure 1

a & b, Immunoblotting analysis of mouse brain homogenate (input), cytosol, and membranes (a), and quantification of protein levels (b; means ± SEMs; n=3)3.

c, Native mouse brain α-synuclein (375 μg) elutes as an apparent tetramer during gel filtration on a Superdex 200 column (top), as analyzed by α-synuclein immunoblotting (bottom).

d, Analysis of purified recombinant myc-epitope-tagged α-synuclein by SDS-PAGE and immunoblotting.

e, Molecular mass calibration curve for gel filtration (Rf = migration distance of proteins versus total running distance).

f, Recombinant myc-tagged human α-synuclein (16 μg) also elutes as an apparent tetramer during gel filtration.

g, Circular dichroism spectroscopy shows that recombinant α-synuclein (10 μg) is unstructured in solution and becomes α-helical upon liposome binding (PS = phosphatidylserine; PC = phosphatidylcholine; molar protein-to-lipid ratio = 1:530).

h, Recombinant (0.5 μg) and α-synuclein in brain cytosol (12 μg total protein) run as apparent tetramers on blue-native gels without boiling or after boiling for 5 min.

i, Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) reveals that recombinant α-synuclein (0.5 mg) is monomeric.

These results seem to confirm that α-synuclein forms a stable tetramer in solution. However, dynamic or unstructured states of a protein may increase its hydrodynamic radius and apparent molecular mass during gel filtration. Indeed, circular dichroism (CD) spectroscopy showed that recombinant α-synuclein lacked detectable secondary structure, but became α-helical upon membrane binding (Fig. 1g). Consistent with the gel-filtration analysis, both native and recombinant α-synuclein migrated as a single band of ~65 kDa on blue-native gels. Strikingly, however, both recombinant and native α-synuclein still migrated at that apparent size after boiling, which disrupts secondary and tertiary structures, arguing against a folded multimer (Fig. 1h). Furthermore, size-exclusion chromatography coupled with multi-angle laser-light scattering (SEC-MALS) revealed that recombinant α-synuclein was monomeric (Fig. 1i). Since native α-synuclein in brain cytosol and recombinant α-synuclein behave identically in gel filtration and blue-native gel-electrophoresis experiments, the SEC-MALS demonstration that recombinant α-synuclein is monomeric suggests that native brain α-synuclein in cytosol is also monomeric.

We next tested whether native brain α-synuclein is still monomeric even when purified. We purified α-synuclein from mouse brain without detergents or denaturing conditions (purity >90%; Fig. 2a). Mass spectrometry showed that native brain α-synuclein was significantly larger than predicted (measured mass, 16,408±894 Da [n=3]; predicted, 14460 Da). The increased mass is partly due to N-terminal acetylation of brain α-synuclein (Fig. 2b)12,13. SEC-MALS revealed that freshly purified native α-synuclein was again predominantly monomeric (Fig. 2c). We additionally observed a plateau along the left shoulder of the main SEC-MALS peak with a mass of ~58 kDa that contained little detectable α-synuclein (<5% by immunoblotting). CD spectroscopy showed a largely random-coil conformation (34–59%) with α-helical contributions (21–24%; Fig. 2d). Purified α-synuclein aggregated, in a time-dependent manner, with a relative increase in overall secondary structure as observed by CD spectroscopy (Fig. 2d), and the appearance of larger particles as uncovered by dynamic light scattering (Fig. 2e).

Figure 2.

Figure 2

a, SDS-PAGE analysis of five stages of α-synuclein purification from mouse brain (IEX, anion exchange chromatography, HIC, hydrophobic interaction chromatography). Purified α-synuclein was also analyzed by immunoblotting and mass spectrometry as shown.

b, Mass spectrometry analysis reveals N-terminal acetylation of native α-synuclein. Shown is an extracted ion chromatogram of the N-terminally acetylated α-synuclein peptide (inset: MSMS spectrum containing the sequence of the N-terminal peptide and identified b and y ions).

c, SEC-MALS shows that purified brain α-synuclein (150 μg) is largely monomeric (main peak with a mass of 17±1 kDa), but includes a minor component (plateau along the left shoulder with a mass of 58±5 kDa) that contains little detectable α-synuclein (see immunoblot in insert). Calculated masses were extracted from marked areas.

d, CD spectroscopy of freshly purified brain α-synuclein (7.5 μM) shows mainly disordered conformations that progressively acquire structured conformations as a result of time- and temperature-dependent aggregation.

e, Purified brain α-synuclein (0.12 mg/ml) rapidly aggregates as measured by dynamic light scattering immediately (0 h) or 152 h after purification.

Our data show that native brain α-synuclein primarily consists of an unstructured monomer, but readily aggregates in a time-dependent manner. This conclusion was demonstrated both for unpurified α-synuclein as a component of brain cytosol (Fig. 1), and for purified α-synuclein in solution (Fig. 2c). Purified brain α-synuclein – analyzed here for the first time – carries significant posttranslational modifications (Fig. 2b), which however do not appear to significantly alter its folding since the biophysical properties of recombinant unmodified α-synuclein and native modified α-synuclein were similar (Figs. 1 and 2). The differences between our results with brain α-synuclein and those obtained with erythrocyte α-synuclein12 may be due to erythrocyte-specific posttranslational modifications, or to time-dependent multimerization/aggregation of erythrocyte α-synuclein that may have been overlooked. Indeed, the CD spectrum of erythrocyte α-synuclein12 is similar to that of purified brain α-synuclein after 75 hour incubation (Fig. 2d). Independent of which explanation will explain our differences in results, the conformationally labile state of native brain α-synuclein documented here provides a potential explanation for why α-synuclein is susceptible to pathological aggregation as observed in multiple neurodegenerative disorders4,5.

METHODS

α-Synuclein was purified from mouse brain cytosol (obtained from brain homogenates by ultracentrifugation at 280,000gav) by sequential chromatography on Q-Sepharose (elution at 0.3–0.5 M NaCl, 20 mM Tris-HCl pH7.4), phenyl-Sepharose (flow-through in 1 M (NH4)2SO4), and Superdex-200 10/300GL. SEC-MALS was performed on a WTC-030S5 column (Heleos OptiLab instruments, Wyatt Technology). Circular dichroism spectra were measured in 25% PBS on an Aviv CD Spectrometer (Model 202-01) and deconvolved (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) with Contin-4 and -7 reference sets. Mass spectrometry was performed on purified α-synuclein or α-synuclein-containing gel pieces digested with Glu-C and Protease Max (Promega using standard procedures14. All other methods were described previously3.

Footnotes

AUTHOR CONTRIBUTIONS

Jacqueline Burré, Sandro Vivona, Jiajie Diao, and Manu Sharma performed the experiments; all authors planned and analyzed the experiments and wrote the paper.

References

  • 1.Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443–9449. doi: 10.1074/jbc.273.16.9443. [DOI] [PubMed] [Google Scholar]
  • 2.Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. α-Synuclein membrane interactions and lipid specificity. J Biol Chem. 2000;275:34328–34334. doi: 10.1074/jbc.M004345200. [DOI] [PubMed] [Google Scholar]
  • 3.Burré J, et al. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663–1667. doi: 10.1126/science.1195227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet. 2011;12:301–25. doi: 10.1146/annurev-genom-082410-101440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson’s disease and α-synuclein expression. Mov Disord. 2011;26:2160–2168. doi: 10.1002/mds.23948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry. 1996;35:13709–13715. doi: 10.1021/bi961799n. [DOI] [PubMed] [Google Scholar]
  • 7.Kim J. Evidence that the precursor protein of non-A beta component of Alzheimer’s disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells. 1997;7:78–83. [PubMed] [Google Scholar]
  • 8.Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem. 2001;276:43495–43498. doi: 10.1074/jbc.C100551200. [DOI] [PubMed] [Google Scholar]
  • 9.Chandra S, Chen X, Rizo J, Jahn R, Südhof TC. A broken α-helix in folded α-synuclein. J Biol Chem. 2003;278:15313–15318. doi: 10.1074/jbc.M213128200. [DOI] [PubMed] [Google Scholar]
  • 10.Lokappa SB, Ulmer TS. α-Synuclein populates both elongated and broken helix states on small unilamellar vesicles. J Biol Chem. 2011;286:21450–21457. doi: 10.1074/jbc.M111.224055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fauvet B, et al. α-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J Biol Chem. 2012;287:15345–15364. doi: 10.1074/jbc.M111.318949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107–110. doi: 10.1038/nature10324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Maltsev AS, Ying J, Bax A. Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties. Biochem. 2012;51:5004–5013. doi: 10.1021/bi300642h. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Johnson H, Eyers CE. Analysis of post-translational modifications by LC-MS/MS. Methods Mol Biol. 2010;658:93–108. doi: 10.1007/978-1-60761-780-8_5. [DOI] [PubMed] [Google Scholar]

RESOURCES